FRANCE 2030: Phost’in Therapeutics is awarded 1.7m€ in the I-NOV competition to support clinical trial and industrialization of its First-In-Class GnT-V inhibitor

Montpellier, France – July 2023, 4th

Phost’in Therapeutics (Montpellier, France), a clinical stage company focused on the discovery and development of N-glycosylation inhibitors for the treatment of cancer and other serious diseases, is proud to announce being a winner in the 9th wave of the highly competitive i-Nov innovation competition.